BuChE K variant is decreased in Alzheimer’s disease not in fronto-temporal dementia

Bizzarro, Alessandra; Guglielmi, Valeria; Lomastro, Rosa; Valenza, Alessandro; Lauria, Alessandra; Marra, Camillo; Silveri, Maria Caterina; Tiziano, Francesco Danilo; Brahe, Christina; Masullo, Carlo

doi:10.1007/s00702-009-0358-y

Cited by 17 publications

(9 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…But differed significantly of studies such as Bizzaro et al [21], which suggest a protective effect of K variant for AD, and differed also of surveys that suggest K variant as a risk factor for AD [22,23]. Podoly et al [24] considered that the controversial results are due to biochemical properties of variant K, which may have ambiguous effect on AD because the same structural features that destabilize BChE variant K are those that make it less effective as a neuroprotector.…”

Section: Discussionmentioning

confidence: 93%

Association analysis between K and −116A variants of butyrylcholinesterase and Alzheimer’s disease in a Brazilian population

Simão-Silva

Bertolucci

Lábio

et al. 2013

Chemico-Biological Interactions

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 93%

Association analysis between K and −116A variants of butyrylcholinesterase and Alzheimer’s disease in a Brazilian population

Simão-Silva

Bertolucci

Lábio

et al. 2013

Chemico-Biological Interactions

View full text Add to dashboard Cite

“…Some of them found the BCHE-K was associated with AD (Lehmann et al, 1997;McIlroy et al, 2000;Raygani et al, 2004;Tilley et al, 1999;Wiebusch et al, 1999) and others found no association (Alvarez-Arcaya et al, 2000;Ki et al, 1999;Singleton et al, 1998). Bizzarro et al (2010), in turn, suggest a protective effect of K variant, since the authors found it in a lower frequency in AD patients when compared to healthy controls and to fronto-temporal dementia (FTD) patients. In contrast to Podoly et al (2009), in the present study it was verified that the K variant acts by reducing G2, G1 and G1-ALB relative activities and not the tetramer (G4), which suffered greater influence of AD itself.…”

Section: Discussionmentioning

confidence: 94%

Butyrylcholinesterase: K variant, plasma activity, molecular forms and rivastigmine treatment in Alzheimer's disease in a Southern Brazilian population

Bono

Simão-Silva

Batistela

et al. 2015

Neurochemistry International

View full text Add to dashboard Cite

Alzheimer's disease (AD) is a neurodegenerative disorder in which there is a decline of cholinergic function. The symptomatic AD treatment involves the use of ChEIs (cholinesterase inhibitors) as rivastigimine, a dual inhibitor. The human butyrylcholinesterase (BChE) is an enzyme that has specific roles in cholinergic neurotransmission and it has been associated with AD. In the serum, BChE is found in four main molecular forms: G1 (monomer); G1-ALB (monomer linked to albumin); G2 (dimer); and G4 (tetramer). The interaction between the products of BCHE gene and CHE2 locus results in CHE2 C5+ and CHE2 C5- phenotypes. CHE2 C5+ phenotype and BChE-K are factors that influence on BChE activity. This work aimed to verify the proportions of BChE molecular forms, total and relative activity in 139 AD patients and 139 elderly controls, taking into account K variant, CHE2 locus, rivastigmine treatment and clinical dementia rating (CDR) of AD patients. Phenotypic frequencies of CHE2 C5+ and frequency of the carriers of the K allele were similar between groups. Total BChE activity in plasma was significantly lower in AD patients than in elderly controls. Furthermore, we found that reduction on plasma BChE activity is associated directly with AD progression in AD patients and that rivastigmine treatment has a stronger effect on BChE activity within the CDR2 group. The reduction in BChE activity did not occur proportionally in all molecular forms. Multiple regression analysis results confirmed that AD acts as the main factor in plasma BChE activity reduction and that severe stages are related with an even greater reduction. These findings suggest that the reduction of total plasma BChE and relative BChE molecular forms activity in AD patients is probably associated with a feedback mechanism and provides a future perspective of using this enzyme as a possible plasmatic secondary marker for AD.

show abstract

“…Some researchers18,32–35 found association between the BChE -K and AD, whereas others17,36 found no association. Alvarez-Arcaya et al11 and Bizzarro et al37 suggested a protective role of BChE -K. The correlation of BChE-K with MCI as well as AD is different between different ethnic groups. Thus, BChE-K may be either a risk or a protective factor in AD 38.…”

Section: Discussionmentioning

confidence: 98%

Association between butyrylcholinesterase K variant and mild cognitive impairment in the Thai community-dwelling patients

Pongthanaracht¹,

Yanarojana²,

Pinthong³

et al. 2017

CIA

View full text Add to dashboard Cite

ObjectiveTo study the association of the butyrylcholinesterase K variant (BChE-K) and the plasma BChE activity with mild cognitive impairment (MCI) in Thai community-dwelling patients.MethodsOne hundred patients diagnosed with MCI and 100 control subjects were recruited from the community-dwelling setting in Bangkok, Thailand. The genotype and allele distributions of the BChE-K were determined by polymerase chain reaction and subsequent DNA sequencing. The BChE activity was measured in plasma according to the Ellman’s method.ResultsThe BChE-K allele frequencies in the Thai community-dwelling patients were in accordance with other ethnics. The BChE-K allele frequency in the control subjects (12%) was higher than that of MCI patients (5.5%), suggesting a protective role of BChE-K for MCI in the Thai community-dwelling patients. The BChE-K homozygotes were significantly associated with lower BChE activity.ConclusionOur results suggested that the BChE-K may be implicated as a protective factor for MCI in the Thai community-dwelling patients, although a further study with a large sample size is warranted to confirm this.

show abstract

BuChE K variant is decreased in Alzheimer’s disease not in fronto-temporal dementia

Cited by 17 publications

References 43 publications

Association analysis between K and −116A variants of butyrylcholinesterase and Alzheimer’s disease in a Brazilian population

Association analysis between K and −116A variants of butyrylcholinesterase and Alzheimer’s disease in a Brazilian population

Butyrylcholinesterase: K variant, plasma activity, molecular forms and rivastigmine treatment in Alzheimer's disease in a Southern Brazilian population

Association between butyrylcholinesterase K variant and mild cognitive impairment in the Thai community-dwelling patients

Contact Info

Product

Resources

About